Risk of selecting K65R in anti retroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir
University of Bonn, Bonn, North Rhine-Westphalia, Germany AIDS
(Impact Factor: 5.55).
12/2005; 19(17):2036-8. DOI: 10.1097/01.aids.0000189563.79976.05
Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not require antiretroviral therapy.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.